A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Aarhus University Hospital
Massachusetts General Hospital
Northwestern University
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Oklahoma
University Health Network, Toronto
University of Wisconsin, Madison
University of Texas Southwestern Medical Center
Incyte Corporation
Tempus AI
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Institut Bergonié
Duke University
University of California, San Francisco
Case Comprehensive Cancer Center
Elevation Oncology
University Hospital, Ghent
Ankara University
Incyte Corporation
University of California, San Diego
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
University Hospital, Ghent
Astellas Pharma Inc
Actuate Therapeutics Inc.
Cancer Trials Ireland
AdventHealth
University of Michigan Rogel Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
University Hospital, Ghent
Icahn School of Medicine at Mount Sinai
Bayer
pharmaand GmbH
Columbia University
Eastern Cooperative Oncology Group
Endocyte
M.D. Anderson Cancer Center
University Hospitals Bristol and Weston NHS Foundation Trust
Seoul National University Hospital
Centre Leon Berard
Mendus
Portland VA Medical Center
James J. Peters Veterans Affairs Medical Center
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Bristol-Myers Squibb
Centre Hospitalier Universitaire de Besancon
AIO-Studien-gGmbH